NCT03336333 · BASELINE

Baseline characteristics

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL · Source last updated 2026-03-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
238
group Id
BG001
value
241
group Id
BG002
value
111
group Id
BG003
value
590
units
Participants

groups

description
Bendamustine + Rituximab in participants with CLL without del(17p); bendamustine 90 milligrams (mg)/m\^2/day administered intravenously (IV) on the first 2 days of each cycle for 6 cycles; rituximab 375 mg/m\^2 for Cycle 1 and 500 mg/m\^2 for Cycles 2 to 6 (each cycle is 28 days)
id
BG000
title
Cohort 1: Bendamustine + Rituximab Without Del(17p)
description
Zanubrutinib in participants with CLL without del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression
id
BG001
title
Cohort 1: Zanubrutinib Without Del(17p)
description
Zanubrutinib in participants with CLL with del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression
id
BG002
title
Cohort 2: Zanubrutinib With Del(17p)
description
Total of all reporting groups
id
BG003
title
Total

measures

calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
<=18 years
measurements
group Id
BG000
value
46
group Id
BG001
value
45
group Id
BG002
value
16
group Id
BG003
value
107
title
Between 18 and 65 years
measurements
group Id
BG000
value
192
group Id
BG001
value
196
group Id
BG002
value
95
group Id
BG003
value
483
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
94
group Id
BG001
value
87
group Id
BG002
value
32
group Id
BG003
value
213
title
Female
measurements
group Id
BG000
value
144
group Id
BG001
value
154
group Id
BG002
value
79
group Id
BG003
value
377
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
5
group Id
BG002
value
1
group Id
BG003
value
10
title
Hispanic or Latino
measurements
group Id
BG000
value
211
group Id
BG001
value
218
group Id
BG002
value
99
group Id
BG003
value
528
title
Not Hispanic or Latino
measurements
group Id
BG000
value
23
group Id
BG001
value
18
group Id
BG002
value
11
group Id
BG003
value
52
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
9
group Id
BG001
value
4
group Id
BG002
value
1
group Id
BG003
value
14
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
1
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
1
group Id
BG001
value
4
group Id
BG002
value
0
group Id
BG003
value
5
title
Black or African American
measurements
group Id
BG000
value
206
group Id
BG001
value
221
group Id
BG002
value
105
group Id
BG003
value
532
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
More than one race
measurements
group Id
BG000
value
22
group Id
BG001
value
11
group Id
BG002
value
5
group Id
BG003
value
38
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants

population Description

Intent-to-treat analysis set included all enrolled participants who were assigned to a treatment group (as of cut-off date of 07MAY2021)

Complete source fields

denoms

counts
group Id
BG000
value
238
group Id
BG001
value
241
group Id
BG002
value
111
group Id
BG003
value
590
units
Participants

groups

description
Bendamustine + Rituximab in participants with CLL without del(17p); bendamustine 90 milligrams (mg)/m\^2/day administered intravenously (IV) on the first 2 days of each cycle for 6 cycles; rituximab 375 mg/m\^2 for Cycle 1 and 500 mg/m\^2 for Cycles 2 to 6 (each cycle is 28 days)
id
BG000
title
Cohort 1: Bendamustine + Rituximab Without Del(17p)
description
Zanubrutinib in participants with CLL without del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression
id
BG001
title
Cohort 1: Zanubrutinib Without Del(17p)
description
Zanubrutinib in participants with CLL with del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression
id
BG002
title
Cohort 2: Zanubrutinib With Del(17p)
description
Total of all reporting groups
id
BG003
title
Total

measures

calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
<=18 years
measurements
group Id
BG000
value
46
group Id
BG001
value
45
group Id
BG002
value
16
group Id
BG003
value
107
title
Between 18 and 65 years
measurements
group Id
BG000
value
192
group Id
BG001
value
196
group Id
BG002
value
95
group Id
BG003
value
483
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
94
group Id
BG001
value
87
group Id
BG002
value
32
group Id
BG003
value
213
title
Female
measurements
group Id
BG000
value
144
group Id
BG001
value
154
group Id
BG002
value
79
group Id
BG003
value
377
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
5
group Id
BG002
value
1
group Id
BG003
value
10
title
Hispanic or Latino
measurements
group Id
BG000
value
211
group Id
BG001
value
218
group Id
BG002
value
99
group Id
BG003
value
528
title
Not Hispanic or Latino
measurements
group Id
BG000
value
23
group Id
BG001
value
18
group Id
BG002
value
11
group Id
BG003
value
52
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
9
group Id
BG001
value
4
group Id
BG002
value
1
group Id
BG003
value
14
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
1
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
1
group Id
BG001
value
4
group Id
BG002
value
0
group Id
BG003
value
5
title
Black or African American
measurements
group Id
BG000
value
206
group Id
BG001
value
221
group Id
BG002
value
105
group Id
BG003
value
532
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
More than one race
measurements
group Id
BG000
value
22
group Id
BG001
value
11
group Id
BG002
value
5
group Id
BG003
value
38
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants

population Description

Intent-to-treat analysis set included all enrolled participants who were assigned to a treatment group (as of cut-off date of 07MAY2021)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice